Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

Max J. Gordon, Lei Feng, Paolo Strati, Hun Ju Lee, Fredrick B. Hagemeister, Jason R. Westin, Felipe Samaniego, Mario L. Marques-Piubelli, Francisco Vega Vazquez, Edwin R. Parra Cuentas, Luisa M. Solis-Soto, Wencai Ma, Jing Wang, Linda Claret, Barbara Averill, Karina Ibanez, Luis E. Fayad, Christopher R. Flowers, Michael R. Green, R. Eric DavisSattva S. Neelapu, Nathan H. Fowler, Loretta J. Nastoupil

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences